← Leaderboards
Bozena Korczak
Vascular Vision Pharmaceuticals Company
$3,058,782
Attributed
$3,058,782
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2022–24$2M$1.5M$1M$500K$0
'22
'23
'24
Funding mix
By agency
NIH$3,058,782 · 1
By mechanism
R44$3,058,782 · 1
Top collaborators
No co-investigators on record.
Most similar at Vascular Vision Pharmaceuticals Company
Same institution · by research overlap
- Shaker A Mousa$3,337,102
- Shaker Mousa$288,945
Others in their field
Other Rising Stars on “Endothelium”
- John Paderi John Paderi John Paderi · Ihp Therapeutics, Inc.$6,183,017
- Andrew Chris Yang · University Of California, San Francisco$4,324,660
- Charles Dimmler III · Ceramedix Holding, Llc$4,223,612
- Sarah Elizabeth Lutz · University Of Illinois At Chicago$3,911,564
- Galina Vid · Ceramedix Holding, Llc$3,007,043
- Ming He · University Of California, San Diego$2,917,239
Research focus
EndotheliumFda ApprovedAffectAccountingFatigueAdoptedBinding ProteinsBlood TransfusionBlood VesselsAdhesionsAfrican American PopulationCellsAlternative TreatmentCessation Of LifeChronicComplexCostDisease ManagementDisease ProgressionDisorder PreventionDoseAfrican AmericanCardiovascular SystemFirst-In-Human
Grant awards (3)
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$1,031,733
R44 · FY2024 · HL · contact PI
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$1,030,837
R44 · FY2023 · HL · contact PI
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$996,212
R44 · FY2022 · HL · contact PI